BioPharma Resources

Drug Trial Radar · NCT03647098

Survival Outcomes of Lung Cancer

Survival Outcomes for Lung Cancer

Last checked: Nov 19, 2026Latest source record: Feb 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20,000

Planned (sponsor's estimate)

Start

Aug 1, 2018

Primary completion

Dec 31, 2028

Study completion Dec 31, 2030

Sponsor

Lead sponsor
Hunan Province Tumor HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 27, 2018

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective study to analyze the survival outcomes of different groups about lung cancer patients.

Conditions

  • Lung Cancer

Interventions

  • TreatmentDrug

    Treatment decisions guided by molecular profiling and clinical judgment of principal investigators

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: Time from first subject dose to study completion, or up to 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.